Drug Profile
PF 06747143
Alternative Names: PF-06747143Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CXCR4 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 30 Jan 2018 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy) in USA (IV) (Pfizer pipeline, March 2018)
- 30 Jan 2018 Discontinued - Phase-I for Acute myeloid leukaemia (Monotherapy) in USA (IV) (Pfizer pipeline, March 2018)
- 28 Nov 2017 Pfizer terminates a phase I trial for Acute myeloid leukaemia (Monotherapy, Combination therapy) in USA (IV) (NCT02954653)